Skip to main content

BARDiag - Biomarker tests for early cancer detection

Objective

Colorectal cancer and lung cancer cause millions of death each year. Currently there is no suitable non-invasive method for the early detection of these types of cancer. The tumour suppressor gene BARD1 (BRCA1-associated RING domain protein) is aberrantly expressed in several types of cancer and could be a diagnostic target for early cancer diagnosis in blood samples. The overall objective of the project is to develop blood tests for the early detection of colorectal and lung cancer based on cancer-specific BARD1 isoforms. The outlined tests will analyse BARD1 isoforms at two levels: the expression of isoform-specific RNA in circulating tumour cells (CTC) and the presence of isoform-specific autoantibodies in serum. To reach these objectives, several technological challenges have to be overcome. The BARDiag consortium includes 3 SMEs and 4 research centres, who have excellent expertise, specific knowledge, the required lab infrastructure and necessary clinical materials that will enable to conduct this project. Within the frame of the project, innovative methods for the isolation of CTCs in colorectal and lung cancer patients will be developed, the specific signatures of the BARD1 isoforms at both mRNA and autoimmune levels will be defined, and assays for the detection of these isoforms will be established, validated with clinical samples and tested for their marketability. The results of the proposed project will have extensive impacts. Not only more scientific knowledge on the expression of BARD1 isoforms in colorectal and lung cancer will be obtained and therefore the understanding for cancer will be improved, but also non-invasive methods for the early detection of colorectal and lung cancer will be made broadly available in form of commercial test kits. The SMEs will extend their expertise and knowledge and therefore strengthen their economic power, which will contribute to increase European competitiveness.

Call for proposal

FP7-SME-2010-1
See other projects for this call

Coordinator

BARD1AG SA
Address
Rue De La Fontaine 7
1204 Geneve
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 695 617,60
Administrative Contact
Christophe Bonny (Dr.)

Participants (7)

Genorama OU
Estonia
EU contribution
€ 100 540
Address
Vaksali 17A
50410 Tartu
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Indrek Kask (Dr.)
pluriSelect Gmbh
Germany
EU contribution
€ 203 320
Address
Kreuzstrasse 5
04103 Leipzig
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jan-Michael Heinrich (Dr.)
UNIVERSITE DE GENEVE
Switzerland
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Irmgard Irminger-Finger (Dr.)
UNIVERSITAET LEIPZIG
Germany
EU contribution
€ 5 000
Address
Ritterstrasse 26
04109 Leipzig
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerhard Fuchs (Mr.)
TARTU ULIKOOL
Estonia
EU contribution
€ 5 769,37
Address
Ulikooli 18
51005 Tartu
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Uri Asko (Dr.)
MEDIZINISCHE UNIVERSITAET WIEN
Austria
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Michael Gnant (Prof.)
VIENNALAB DIAGNOSTICS GMBH

Participation ended

Austria
EU contribution
€ 10 375,69
Address
Gaudenzdorfer Guertel 43-45
1120 Vienna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andreas Kofler (Prof.)